Tags

Type your tag names separated by a space and hit enter

[Management of gastrinoma].
Presse Med. 2016 Nov; 45(11):986-991.PM

Abstract

Gastrinoma is a very rare tumor leading to gastrin hypersecretion and characterised by Zollinger-Ellisson syndrome (ZES) i.e. severe gastric and duodenal ulceration and profuse diarrhea. This disease can be sporadic or familial within a multiple endocrine neoplasia type 1 (MEN-1) syndrome. Diagnosis is based on hypergastrinemia/hypercholrhydria. Tumors are usually located in the duodeno-pancreas. Preoperative tumor location by CT, echoendoscopy and fibroscopy is not always possible because of the small size of the lesion that are frequently multiple. The aim of gastrinoma treatment is 1/to control the hormonal hypersecretion 2/to remove the neoplasm when it is possible. Surgery is the only chance to cure. Gastrinoma is a slow-growing tumor, and overall survival is good with a median survival above 10years and a 5-year survival above 80 % in surgically resected patients. Recurrence is frequent, a biochemical recurrence is observed in 65 % of cases and morphological recurrence in 40 % of patients at 2years. Metastases are associated with a dismal prognosis.

Authors+Show Affiliations

AP-HP, hôpital Cochin, service de chirurgie digestive hépato-biliaire et endocrienne, Paris, France.AP-HP, hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France.AP-HP, hôpital Cochin, service de chirurgie digestive hépato-biliaire et endocrienne, Paris, France; Université Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France.AP-HP, hôpital Cochin, service de chirurgie digestive hépato-biliaire et endocrienne, Paris, France; Université Paris Descartes, 12, rue de l'École-de-Médecine, 75006 Paris, France. Electronic address: sebastien.gaujoux@aphp.fr.

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

27262229

Citation

Hain, Elisabeth, et al. "[Management of Gastrinoma]." Presse Medicale (Paris, France : 1983), vol. 45, no. 11, 2016, pp. 986-991.
Hain E, Coriat R, Dousset B, et al. [Management of gastrinoma]. Presse Med. 2016;45(11):986-991.
Hain, E., Coriat, R., Dousset, B., & Gaujoux, S. (2016). [Management of gastrinoma]. Presse Medicale (Paris, France : 1983), 45(11), 986-991. https://doi.org/10.1016/j.lpm.2016.04.012
Hain E, et al. [Management of Gastrinoma]. Presse Med. 2016;45(11):986-991. PubMed PMID: 27262229.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Management of gastrinoma]. AU - Hain,Elisabeth, AU - Coriat,Romain, AU - Dousset,Bertrand, AU - Gaujoux,Sébastien, Y1 - 2016/06/01/ PY - 2016/04/18/received PY - 2016/04/19/accepted PY - 2016/6/6/pubmed PY - 2017/1/24/medline PY - 2016/6/6/entrez SP - 986 EP - 991 JF - Presse medicale (Paris, France : 1983) JO - Presse Med VL - 45 IS - 11 N2 - Gastrinoma is a very rare tumor leading to gastrin hypersecretion and characterised by Zollinger-Ellisson syndrome (ZES) i.e. severe gastric and duodenal ulceration and profuse diarrhea. This disease can be sporadic or familial within a multiple endocrine neoplasia type 1 (MEN-1) syndrome. Diagnosis is based on hypergastrinemia/hypercholrhydria. Tumors are usually located in the duodeno-pancreas. Preoperative tumor location by CT, echoendoscopy and fibroscopy is not always possible because of the small size of the lesion that are frequently multiple. The aim of gastrinoma treatment is 1/to control the hormonal hypersecretion 2/to remove the neoplasm when it is possible. Surgery is the only chance to cure. Gastrinoma is a slow-growing tumor, and overall survival is good with a median survival above 10years and a 5-year survival above 80 % in surgically resected patients. Recurrence is frequent, a biochemical recurrence is observed in 65 % of cases and morphological recurrence in 40 % of patients at 2years. Metastases are associated with a dismal prognosis. SN - 2213-0276 UR - https://www.unboundmedicine.com/medline/citation/27262229/[Management_of_gastrinoma]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0755-4982(16)30069-0 DB - PRIME DP - Unbound Medicine ER -